Inflammatory Breast Cancer: a Separate Entity

No abstract is available for this paper.

• Publication year

  2019

• Venue

  Current Oncology Reports

• Publication date

  2019-08-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11912-019-0842-yPMID 31414257
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Epigenetics in Inflammatory Breast Cancer: Biological Features and Therapeutic Perspectives

  2020cited by this paper
• Patterns of breast reconstruction in patients diagnosed with inflammatory breast cancer: The Dana‐Farber Cancer Institute's Inflammatory Breast Cancer Program experience

  2020cited by this paper
• Inflammatory Breast Cancer Promotes Development of M2 Tumor-associated Macrophages and Cancer Mesenchymal Cells Through a Complex Cytokine Network.

  2019cited by this paper
• Adjuvant Systemic Treatment of Premenopausal Women With Hormone Receptor-Positive Early Breast Cancer: Lights and Shadows.

  2019cited by this paper
• Metabolic Characterization of Inflammatory Breast Cancer With Baseline FDG‐PET/CT: Relationship With Pathologic Response After Neoadjuvant Chemotherapy, Receptor Status, and Tumor Grade

  2019cited by this paper
• Abstract PD3-08: Assessment of the tumor immune environment in inflammatory breast cancer treated with neoadjuvant dual-HER2 blockade

  2019cited by this paper
• Trastuzumab Emtansine for Residual Invasive HER2‐Positive Breast Cancer

  2019cited by this paper
• Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer

  2019cited by this paper
• Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer

  2018cited by this paper
• Concurrent Veliparib With Chest Wall and Nodal Radiotherapy in Patients With Inflammatory or Locoregionally Recurrent Breast Cancer: The TBCRC 024 Phase I Multicenter Study.

  2018cited by this paper
• Mammary stem cell and macrophage markers are enriched in normal tissue adjacent to inflammatory breast cancer

  2018cited by this paper
• Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer.

  2018cited by this paper
• International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference

  2018cited by this paper
• Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer

  2018cited by this paper
• University of Birmingham International consensus on the clinical management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer research program 10th anniversary conference

  2018cited by this paper
• A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity.

  2018cited by this paper
• Inflammatory breast cancer biology: the tumour microenvironment is key

  2018cited by this paper
• Abstract OT3-05-01: TBCRC 039: Phase II study of combination ruxolitinib (INCB018424) with preoperative chemotherapy for triple negative inflammatory breast cancer

  2018cited by this paper
• The Impact of Subtype Distribution in Inflammatory Breast Cancer Outcome.

  2018cited by this paper
• The Impact of Locoregional Therapy in Nonmetastatic Inflammatory Breast Cancer: A Population-Based Study

  2018cited by this paper
• Influence of Biologic Subtype of Inflammatory Breast Cancer on Response to Neoadjuvant Therapy and Cancer Outcomes

  2017cited by this paper
• Improved Locoregional Control in a Contemporary Cohort of Nonmetastatic Inflammatory Breast Cancer Patients Undergoing Surgery

  2017cited by this paper
• Comparative aspects of canine and human inflammatory breast cancer.

  2017cited by this paper
• Challenging a Misnomer? The Role of Inflammatory Pathways in Inflammatory Breast Cancer

  2017cited by this paper
• Adjuvant Pertuzumab and Trastuzumab in Early HER2‐Positive Breast Cancer

  2017cited by this paper
• Inflammatory breast cancer: a model for investigating cluster-based dissemination

  2017cited by this paper
• The Impact of Residual Disease After Preoperative Systemic Therapy on Clinical Outcomes in Patients with Inflammatory Breast Cancer

  2017cited by this paper
• Prospective Feasibility Trial of Sentinel Lymph Node Biopsy in the Setting of Inflammatory Breast Cancer

  2017cited by this paper
• Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.

  2017cited by this paper
• A standard mastectomy should not be the only recommended breast surgical treatment for non-metastatic inflammatory breast cancer: A large population-based study in the Surveillance, Epidemiology, and End Results database 18.

  2017cited by this paper
• Bisphenol A activates EGFR and ERK promoting proliferation, tumor spheroid formation and resistance to EGFR pathway inhibition in estrogen receptor-negative inflammatory breast cancer cells

  2017cited by this paper
• Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy

  2017cited by this paper
• Abstract P6-18-02: Patterns of breast reconstruction in patients diagnosed with inflammatory breast cancer

  2016cited by this paper
• Outcomes of patients with inflammatory breast cancer treated by breast-conserving surgery

  2016cited by this paper
• Steroid Tumor Environment in Male and Female Mice Model of Canine and Human Inflammatory Breast Cancer

  2016cited by this paper
• Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer

  2016cited by this paper
• Mesenchymal stem cells and macrophages interact through IL-6 to promote inflammatory breast cancer in pre-clinical models

  2016cited by this paper
• 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.

  2016cited by this paper
• Polyclonal breast cancer metastases arise from collective dissemination of keratin 14-expressing tumor cell clusters

  2016cited by this paper
• Inflammatory TNBC Breast Cancer: Demography and Clinical Outcome in a Large Cohort of Patients With TNBC.

  2016cited by this paper
• Mesenchymal stem cells mediate the clinical phenotype of inflammatory breast cancer in a preclinical model

  2015cited by this paper
• Inflammatory breast cancer: unique biological and therapeutic considerations.

  2015cited by this paper
• PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy

  2015cited by this paper
• Inflammatory breast cancer and development of brain metastases: risk factors and outcomes

  2015cited by this paper
• Anti-HER2 CD4+ T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer

  2015cited by this paper
• Inflammatory breast cancer: time to standardise diagnosis assessment and management, and for the joining of forces to facilitate effective research

  2015cited by this paper
• Molecular subtypes in patients with inflammatory breast cancer; a single center experience.

  2015cited by this paper
• Inflammatory Breast Cancer: Patterns of Failure and the Case for Aggressive Locoregional Management

  2015cited by this paper
• A Comparison of Criteria to Identify Inflammatory Breast Cancer Cases from Medical Records and the Surveillance, Epidemiology and End Results Data base, 2007–2009

  2014cited by this paper
• Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival.

  2014cited by this paper
• Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.

  2014cited by this paper
• Long-term Follow-up of Breast-conserving Therapy in Patients with Inflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy

  2014cited by this paper
• Primary tumor resection as a component of multimodality treatment may improve local control and survival in patients with stage IV inflammatory breast cancer

  2014cited by this paper
• Underuse of trimodality treatment affects survival for patients with inflammatory breast cancer: an analysis of treatment and survival trends from the National Cancer Database.

  2014cited by this paper
• Simvastatin Radiosensitizes Differentiated and Stem‐Like Breast Cancer Cell Lines and Is Associated With Improved Local Control in Inflammatory Breast Cancer Patients Treated With Postmastectomy Radiation

  2014cited by this paper
• Postmastectomy radiation therapy for inflammatory breast cancer: is more better?

  2014cited by this paper
• Genomic and expression analysis of microdissected inflammatory breast cancer

  2013cited by this paper
• Inflammatory breast cancer: New factors contribute to disease etiology: A review

  2013cited by this paper
• Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).

  2013cited by this paper
• Quantitative high-throughput efficacy profiling of approved oncology drugs in inflammatory breast cancer models of acquired drug resistance and re-sensitization.

  2013cited by this paper
• 18F-FDG PET/CT in Staging Patients with Locally Advanced or Inflammatory Breast Cancer: Comparison to Conventional Staging

  2013cited by this paper
• Uncovering the Molecular Secrets of Inflammatory Breast Cancer Biology: An Integrated Analysis of Three Distinct Affymetrix Gene Expression Datasets

  2013cited by this paper
• Modeling and characterization of inflammatory breast cancer emboli grown in vitro

  2013cited by this paper
• Pretreatment staging positron emission tomography/computed tomography in patients with inflammatory breast cancer influences radiation treatment field designs.

  2012cited by this paper
• Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.

  2012cited by this paper
• Evaluation of lymphangiogenic factors, vascular endothelial growth factor D and E-cadherin in distinguishing inflammatory from locally advanced breast cancer.

  2012cited by this paper
• E-cadherin's dark side: possible role in tumor progression.

  2012cited by this paper
• International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment.

  2011cited by this paper
• Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer.

  2011cited by this paper
• The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors.

  2011cited by this paper
• Trastuzumab in Primary Inflammatory Breast Cancer (IBC): High Pathological Response Rates and Improved Outcome

  2010cited by this paper
• Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Reverses Mesenchymal to Epithelial Phenotype and Inhibits Metastasis in Inflammatory Breast Cancer

  2009cited by this paper
• Locoregional treatment outcomes after multimodality management of inflammatory breast cancer.

  2008cited by this paper
• The lymphovascular embolus of inflammatory breast cancer expresses a stem cell-like phenotype.

  2008cited by this paper
• The impact of immediate breast reconstruction on the technical delivery of postmastectomy radiotherapy.

  2006cited by this paper
• Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute.

  2005cited by this paper
• High incidence of HER-2 positivity in inflammatory breast cancer.

  2004cited by this paper
• Immediate breast reconstruction after mastectomy increases wound complications: however, initiation of adjuvant chemotherapy is not delayed.

  2004cited by this paper
• Mitogen activated protein kinase pathway is involved in RhoC GTPase induced motility, invasion and angiogenesis in inflammatory breast cancer

  2004cited by this paper
• Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor.

  2002cited by this paper
• AJCC Cancer Staging Manual. 6th ed

  2002cited by this paper
• Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer

  2002cited by this paper
• AJCC Cancer Staging Manual

  2002cited by this paper
• Inflammatory carcinoma of the breast

  1978cited by this paper

• Molecular and socioeconomic characteristics of inflammatory breast cancer in the Carolina Breast Cancer Study

  2026cites this paper
• Molecular Subtypes and Mechanisms of Breast Cancer: Precision Medicine Approaches for Targeted Therapies

  2025cites this paper
• From in silico prediction to experimental validation: Identification of drugs and novel synergistic combinations that inhibit growth of inflammatory breast cancer cells

  2025cites this paper
• Racial and ethnic disparities in survival outcomes among patients with inflammatory breast cancer: a systematic review and meta-analysis

  2025cites this paper
• An Unusual Diagnostic Journey of a Spontaneously Resolving Breast Mass: When Rare Entities Cause Concerning Presentations

  2025cites this paper
• Two-sample Mendelian Randomization to evaluate the causal relationship between inflammatory arthritis and female-specific cancers

  2024cites this paper
• Obesity-Associated Breast Cancer: Analysis of Risk Factors and Current Clinical Evaluation.

  2024cites this paper
• Male inflammatory breast cancer: An analysis

  2024cites this paper
• Conserving surgery in inflammatory breast cancer after neoadjuvant chemotherapy in patients with clinical complete response: the ConSIBreC randomized controlled trial

  2024cites this paper
• Applying a Gene Reversal Rate Computational Methodology to Identify Drugs for a Rare Cancer: Inflammatory Breast Cancer

  2023cites this paper
• Complete response in the axilla and the non-triple negative subtype are favourable prognostic factors for survival outcomes in inflammatory breast cancer

  2023cites this paper
• FTO is a major genetic link between breast cancer, obesity, and diabetes

  2023cites this paper
• Current Status of Diagnosis and Management of Inflammatory Breast Cancer

  2023cites this paper
• Proactive Immunotherapeutic Approaches against Inflammatory Breast Cancer May Improve Patient Outcomes

  2022cites this paper
• Inflammatory breast cancer defined: proposed common diagnostic criteria to guide treatment and research

  2022cites this paper
• Paracrine IL-6 Signaling Confers Proliferation between Heterogeneous Inflammatory Breast Cancer Sub-Clones

  2022cites this paper
• A vicious circle in breast cancer: The interplay between inflammation, reactive oxygen species, and microRNAs

  2022cites this paper
• Dermal Lymphatic Invasion, Survival, and Time to Recurrence or Progression in Inflammatory Breast Cancer

  2021cites this paper
• Inflammatory breast cancer, trimodal treatment, and mortality: Does where you live matter?

  2021cites this paper
• Pannikulitis der Mamma – eine seltene Differenzialdiagnose der Mamma

  2021cites this paper
• High endogenous CCL2 expression promotes the aggressive phenotype of human inflammatory breast cancer

  2021cites this paper
• MRI Changes in Breast Skin Following Preoperative Therapy for Patients with Inflammatory Breast Cancer.

  2021cites this paper
• Inflammatory breast cancer appearance at presentation is associated with overall survival

  2021cites this paper
• Epigenetics in Inflammatory Breast Cancer: Biological Features and Therapeutic Perspectives

  2020cites this paper
• Gene expression profiles of inflammatory breast cancer reveal high heterogeneity across the epithelial-hybrid-mesenchymal spectrum

  2020cites this paper
• The Development and Treatment of Lymphatic Dysfunction in Cancer Patients and Survivors

  2020cites this paper
• An unusual cutaneous manifestation of inflammatory breast carcinoma

  2020cites this paper
• Multi-center investigation of the clinical and pathological characteristics of inflammatory breast cancer based on Chinese Society of Breast Surgery (CSBrs-007)

  2020cites this paper
• Literature-Wide Association Studies (LWAS) for a Rare Disease: Drug Repurposing for Inflammatory Breast Cancer

  2020cites this paper
• Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer

  2019cites this paper
• Gene expression profiles of inflammatory breast cancer reveal high heterogeneity across the epithelial-hybrid-mesenchymal spectrum

  year unknowncites this paper